UbiQ is a spin-out from the Netherlands Cancer Institute. We develop and sell ubiquitin research tools and we develop and commercialize HTS assay reagents to Pharma and Biotech companies. Next to our reagent business, we develop specific HTS assays and we conduct HTS DUB inhibitor programs to discover new targeted drugs, both as internal development as well as partnered.
Founded: October 2010
Situated in Amsterdam Science Park: June 2013
Number of employees: 5